Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (28291)	2/21/1999 2:14:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< I think it's clear that many of the readers of this board still lack a clear understanding of the science and technology behind drug development. >> You got that right! A lot of us are counting on your knowledge and confidence in Ligand's science, IMHO. I had to read and reread your note several times. I don't mind you flunking me on "Rexinoids 101" as long as LGND hits $18 some time this year! <g> << All three rexinoids (Targretin, LGD1268 and LGD1324) activate all three RXRs (alpha, beta, gamma). >> From your explanation, the next generation rexinoid should only activate RXRalpha, not RXRbeta or RXRgamma, and must not metabolite into one that activates triglyceride elevating RARs. From the fact that Lilly and Ligand are continuing with the diabetes program, it sounds like they have made progress towards this achievement. I still don't understand why a company would pay Ligand "up front" for being able to distribute Targretin for cancer, if Targretin hasn't been approved yet. Thanks, Bob